Thornton & Ross News

Derma Boy

Derma new business shows steady growth

November 2012
Steady growth from a new range of products in a new business area means development plans are succeeding for T&R Derma.

Our Derma range of emollient products to treat and manage eczema was launched in July 2010 at Britain’s leading dermatology congress, run by the British Association of Dermatology (BAD).

A new sales structure has been established to spearhead growth nationwide, and Dermatology Marketing Manager Janet Maclean has masterminded the launch campaign.

“It’s been slow but steady growth since we launched – which is exactly what we’re hoping for,” explained Janet. “It’s a completely new business area for us – so we haven’t just been launching a new range of products, we’ve been launching Thornton & Ross into a different market - the NHS. It’s part of the long-term strategy for business growth. Britain has a £140 million emollient market – growing by 10% every year due to lifestyle impacts, the rise in population, and the rise in the percentage of elderly. It’s an all-year-round business, not seasonal, and once someone is on an emollient they may use it for their life time. So it has huge potential for us, and we’re laying down the foundations for future growth.”

We have two product ranges within the T&R Derma portfolio. – the cost-effective Zeroderma range of four creams, 2 bath oil products and 1 ointment for hospitals and Primary Care Trusts, which is complemented by a unique, clinically proven product called Aquamol. Aquamol has a unique moisture-enhancing formula combining penetration enhancers and occlusive properties. Few comparable products are clinically proven and Aquamol has been shown to significantly improve eczema and the overall skin condition; significantly reduce skin itch; significantly reduce sleep disturbance and, crucially, reduce the need for topical corticosteroids.


STADA to Become a Major Pharma Player in Ukraine by Acquiring Biopharma's Pharmaceutical Prescription and Consumer Health Business

The STADA Group continues its growth trajectory in Europe. The company, announced that it is acquiring the pharmaceutical business of Biopharma, one of the key pharmaceutical producers in Ukraine.

Click for more info

Is veganism good for your health?

The Future of Your Health report indicates that nearly a third of Brits don’t think so

Click for more info


Biopharmaceutical company Alvotech and global pharmaceutical company STADA Arzneimittel AG ("STADA") today announced that they have entered into an exclusive strategic partnership for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe.

Click for more info

STADA invests $660 Million USD in Takeda's OTC portfolio in Russia/CIS to become a major player in these branded markets

STADA to acquire a portfolio of approximately 20 selected OTC and prescription pharmaceutical products in Russia, Georgia and CIS countries

Click for more info

STADA to acquire Walmark - a leading Consumer Healthcare company in Central Europe

STADA Arzneimittel AG ('STADA' or 'the Group') today announces the acquisition of Walmark a.s. ('Walmark' or 'the company') from Mid Europa Partners for an undisclosed consideration.

Click for more info

Q&A 2019 Pharmacy Show

A Q&A Session with Phoebe Buckley on the 2019 Pharmacy Show

Click for more info

STADA Health Report 2019

More than half of people in UK are optimistic about the future of health

Click for more info

Leading pharmaceutical company invests in seven-figure state-of-the-art facility

Huddersfield pharmaceutical company Thornton & Ross is expanding, with a new seven-figure state-of-the-art facility due to open at the beginning of January.

Click for more info

>> News Archive